title: Circulating ghrelin levels in girls with central precocious puberty are reduced during treatment with LHRH analog.
abstract: Decreased levels of ghrelin have been measured in growing children during puberty. No data are available for girls with central precocious puberty (CPP).
  
  
  OBJECTIVE
  To explore ghrelin changes before, during, and after GnRH analog treatment in girls with CPP.
  
  
  METHODS
  A sample of 20 Caucasian girls (8.08 +/- 0.65 years of age) with CPP was recruited. Height and weight, bone age, LH, FSH, 17beta estradiol (E(2)), and ghrelin were measured before starting treatment with GnRH analog, 18 months after therapy began and again 6 months after therapy discontinuation.
  
  
  RESULTS
  LH and E(2) serum levels decreased significantly during treatment (2.45 +/- 2.03 vs 0.67 +/- 0.49 UI/l, P < 0.01 and 28.17 +/- 9.7 vs 15 pmol/l, P < 0.01 respectively), returning to baseline levels after the discontinuation of therapy (4.75 +/- 1.66 UI/l and 29.23 +/- 6.99 pmol/l respectively). LH peaked following LHRH stimulation significantly (P < 0.01) decreased during treatment (24.45 +/- 14.17 vs 1.3 +/- 0.18 UI/l) and then increased after therapy discontinuation (12.58 +/- 6.09, P < 0.01). Ghrelin decreased significantly (P < 0.05) during treatment (1849 +/- 322 vs 1207 +/- 637 pg/ml), and increased, though not significantly (P = 0.09) after therapy withdrawal (1567 +/- 629 pg/ml).
  
  
  CONCLUSIONS
  Contrary to what is expected in physiologic puberty, where ghrelin is progressively reduced, the prepubertal hormone milieau induced by GnRHa treatment in patients suffering from central precocious puberty (CPP) did not promote an increase in ghrelin circulating levels. Therefore, in CPP, ghrelin secretion seems to be independent from pubertal development per se. Concomitant estrogen suppression during treatment may play a potential role in the regulation of ghrelin secretion in these girls.
authors.affiliation: Department of Mother and Child, Biology-Genetics, Section of Pediatrics, Endocrinology Unit, University of Verona, P.le L.A. Scuro, 10, 37134 Verona, Italy. claudio.maffeis@univr.it
authors.forename: Claudio
authors.initials: C
authors.lastname: Maffeis
authors.forename: Roberto
authors.initials: R
authors.lastname: Franceschi
authors.forename: Paolo
authors.initials: P
authors.lastname: Moghetti
authors.forename: Marta
authors.initials: M
authors.lastname: Camilot
authors.forename: Silvana
authors.initials: S
authors.lastname: Lauriola
authors.forename: Luciano
authors.initials: L
authors.lastname: Tatò
mesh_terms: D001827:Body Height / Q000187:drug effects; D001846:Bone Development / Q000502:physiology; D002648:Child; D004958:Estradiol / Q000097:blood; D005260:Female; D054439:Ghrelin; D012739:Gonadal Steroid Hormones / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006128:Growth / Q000502:physiology; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D036361:Peptide Hormones / Q000097:blood*; D011629:Puberty, Precocious / Q000097:blood* / Q000188:drug therapy*
chemical_list: D054439:Ghrelin; D012739:Gonadal Steroid Hormones; D036361:Peptide Hormones; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007986:Luteinizing Hormone